High Purity CO-1686

Min.Order / FOB Price:Get Latest Price

1 Gram	FOB Price: USD 100.0000

1 Gram

FOB Price: USD 100.0000

Min.Order :1 Gram
Purity: 99%min
Payment Terms : L/C,T/T,

Keywords

CO-1686 EGFR-TKI inhibitors,Romotinib CAS NO.1374640-70-6

Quick Details

Appearance:white solid powder
Application:Only for research,anti-tumor drug substance
PackAge:1g or as buyer's request
ProductionCapacity:100|Kilogram|Month
Storage:shading, sealed.
Transportation:5-15 days after received the advanced payment,by sea,by plane or express, as DHL/TNT/EMS/FEDEX and so on

Superiority:

1. Best service, competitive price, high quality

2. Clients can choose the package's Courier (EMS, DHL, FedEx, UPS,TNT);

3.Clients can choose the packing way for his produccts from many recent effective packing ways;

4.Specials are possible when client's order is big enough, including the discount policy;

5.Our company promises to deliver clients' product to his hands safely, or we'll bear the total loss and resend in time;

6. We accept T/T, West Union. You can choose any term you like

7. Welcome all the customers to visit!

8. High quality, best service,competitive price are our principle

Details:

[Company Profile]

Name:Hebei Luspharm Trading Co.,Ltd.

Year established: 2015

Main product: Intermediates,API,Pharmaceutical Preparation,Botanical Extract,Food Color,Pigments,Dyestuffs,Pesticides,Veterinary Drug,Chemicals,Other product

[Specification]

Product Number	LUSAPI2492
Product Name:	CO-1686
CAS No.	1374640-70-6
English Alias:	Romotinib;Clovis CO-1686
Specifications:	99%MIN
Formula:	C27H28F3N7O3
Molecular Weight:	555.5515296
Package:	10g/tin、50g/bag、100G/bottle
Appearance:	white solid powder

Features: CO-1686 is a novel, oral, selective, covalent TKI that targets the usual activation of EGFR mutations and T790M, leaving wt-EGFR idle and has less side effects.

Application: anti-tumor drug substance; T790M + epidermal growth factor receptor (EGFR) mutations in non-small cell lung AI, CO-1686 has good tolerance and efficacy. Is a novel, irreversible and oral delivery of kinase inhibitors, specifically for mutations in the epidermal growth factor receptor, including T790M (IC50 = 21 nm).

[COMPANY]